Transitioning from traditional to novel anticoagulants: The impact of oral direct thrombin inhibitors on anticoagulation management

Pharmacotherapy

Volumn 24, Issue 10 I, 2004, Pages

  Nutescu, Edith A ^a   Spinler, Sarah A ^b   Dager, William E ^c   Bussey, Henry I ^d,e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e MC 886 ^*

Author keywords

Anticoagulants; Anticoagulation management services; Comprehensive antithrombosis centers; Oral direct thrombin inhibitors; Thrombosis

Indexed keywords

AMINOTRANSFERASE; ANISINDIONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; COUMARIN; HEPARIN; MELAGATRAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; DRUG MONITORING; HUMAN; PATIENT CARE; REVIEW; SIDE EFFECT; STROKE; THROMBOSIS; TRADITIONAL MEDICINE; TREATMENT INDICATION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG MONITORING; DRUG THERAPY; HUMANS; THROMBIN;

EID: 4644286218     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.15.199S.43159     Document Type: Review

References (15)

1. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119:225-38.
2. Sam C, Speckman J, Moskowitz M, Ansell J. The management of warfarin therapy by anticoagulation clinics: results of a forum survey. Anticoagulation Forum Newsletter 2000;5(2):1-4.
3. Nutescu EA, Pickard AS, Blackburn JC, et al. Impact of oral direct thrombin inhibitors on anticoagulation clinics. Pharmacotherapy 2004;24(9):1204-12.
4. Gray DR, Garabedian-Ruffalo SM, Chretien SD. Cost justification of a clinical pharmacist-managed anticoagulation clinic. Drug Intell Clin Pharm 1985;19:575-80.
5. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic and usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998;158:1641-7.
6. Wilt VM, Gums JG, Ahmed OI, et al. Pharmacy operated anticoagulation service: improved outcomes in patients on warfarin. Pharmacotherapy 1995;15:732-79.
7. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from two communities. Arch Intern Med 2000;160:967-73.
8. Nutescu EA, Wittkowsky AK. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 2004;38(1):99-109.
9. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J Intern Med 2003;254(4):322-34.
10. Crowther MA, Weitz JI. Ximelagatran: the first oral direct thrombin inhibitor. Expert Opin Investig Drugs 2004;13(4):403-13.
11. Evans HC, Perry CM, Faulds D. Ximelagatran/melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. Drugs 2004;64(6):649-78.
12. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H, for the THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349(18):1713-21.
13. Olsson SB, for the Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362(9397):1691-8.
14. Nutescu EA. The future of anticoagulation clinics. J Thromb Thrombolysis 2003;16(1-2):61-3.
15. Spyropoulos AC, Haire W. The clinical thrombosis center and clinical thrombologist: a new U.S. health systems paradigm for the management of venous thromboembolic disease. J Thromb Thrombolysis 2003;15(3):227-32.